Life Sciences Blog
Feature
Millennial professionals say that achieving work-life integration is more important than all other job-related goals, including building wealth, according to a survey conducted by World Services Group. >
Services
Region
Industries
- Agriculture
- Corporate & Business
- Crossborder Trade & Investment
- Dispute Resolution
- Employment & Labor
- Energy & Natural Resources
- Environmental
- Financial Services
- Government & Public Sector
- Healthcare & Pharmaceuticals
- Hospitality, Media & Leisure
- Industrial & Manufacturing
- Insurance
- Life Sciences
- Real Estate & Construction
- Retail & Distribution
- Taxation
- Technology
- Telecommunications
- Transportation
Recent Posts
- Blog: Ireland IP & Technology Law BlogEuropean Banking Authority Recommendations on Outsourcing to Cloud Service ProvidersPosted on June 18, 2018 by Mark RasdaleLast week MoneyConf firmly put Dublin in the Fintech spotlight. The pressure on financial services firms to make better use of technology to reduce costs and improve customer service shows no sign of relenting. At the same time they need to carefully navigate the related regulatory challenges around technology outsourcing. A member of the ECB...Continue Reading…
- Blog: Waller Law BlogOne of the hidden benefits of Regulation A+ offerings: variable pricingPosted on June 18, 2018 by Marc J. Adesso
- Blog: Biologics BlogFirst Decision on Label Carve-Outs for Biosimilars Expected in Enbrel LitigationPosted on June 17, 2018 by As biosimilar litigation between Amgen, the maker of Enbrel® (etanercept), and Sandoz, the maker of biosimilar ErelziTM (etanercept-szzs) heads toward trial before Judge Claire Cecchi in the District of New Jersey, Sandoz is seeking to stave off Amgen’s infringement claims for three of the patents in suit by pointing to its recent amendment to the [...]
- Blog: EndpointsFederal “Right to Try”: Don’t Disregard Your State Laws Just Yet!Posted on June 12, 2018 by Academic and Clinical Research GroupHow Federal Preemption (or Lack Thereof) Could Influence the Use of Federal “Right to Try” As discussed in our Alert of June 4, “Right to Try” Comes to the Federal Stage: What Stakeholders Should Do Now, manufacturers, patients, providers and IRBs are now grappling with two alternative federal pathways through which manufacturers may (but are not required) to provide investigational drugs for treatment purposes outside of an FDA-overseen clinical investigation. As manufacturers, treating physicians, institutions, and other stakeholders pause to consider [...]
